After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
Starglo isn't applicable to a US population, an adcom rules.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
PF-08046037 joins PF-08046054 in clinical development.
